What are the risks associated with corporate investment in cancer research?
Investing in cancer research involves several risks. The primary risk is the uncertainty of research outcomes; not all projects lead to successful treatments or profitable products. Additionally, the drug development process is lengthy and costly, often taking over a decade and billions of dollars to bring a new treatment to market. Regulatory challenges and competition from other companies can also pose significant risks. Despite these challenges, successful investments can lead to groundbreaking innovations and substantial financial returns.
